Neuren Pharmaceuticals Ltd has released a press release.
Trofinetide marketing application submitted in Europe
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
In the deck
Earlier from Neuren Pharmaceuticals
- Neuren announces A$50m on-market share buy-back program
- Q3 2024 update
- PRV sold for US$150m - Neuren to receive one third
- DAYBUE receives marketing authorization in Canada
- NEU continues PMS P3 preparations after positive FDA meeting
Later from Neuren Pharmaceuticals
- Priority Review Voucher sale proceeds received
- Fast Track granted by FDA for NNZ-2591 in Pitt Hopkins
- Neuren receives Rare Pediatric Disease Designation from FDA
- DAYBUE (trofinetide) 2024 net sales US$348 million
- Appendix 4E and 2024 full year accounts
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals